Skip to main content
. 2022 Apr 8;14(8):1877. doi: 10.3390/cancers14081877

Figure 6.

Figure 6

Effects of docetaxel and TH1902 on ES-2 and SKOV3 ovarian cancer xenografts. Comparative efficacy of docetaxel and TH1902 on ovarian cancer xenografts tumor growth. Immunodeficient mice bearing subcutaneous ES-2 (A) or SKOV3 (B) tumors were intravenously injected weekly with either vehicle, docetaxel (at its MTD and quarter MTD doses; 15 and 3.75 mg/kg, respectively), or TH1902 (at a dosage which contains a quantity of bound docetaxel equal to the docetaxel doses; 35 and 8.75 mg/kg, respectively), as described in the methods section. Mice in the ES-2 study were euthanized at vehicle group endpoint (Day 18), whereas indicated groups in SKOV3 study were monitored for a prolonged period up to Day 46 post start of treatments. Three cycles of docetaxel at 15 mg/kg were considered MTD. Colored dots below the abscissa indicate drug treatment events for all groups. Data are represented as mean ± SEM (n = 6 mice/group).